This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why Investors Are Snapping Up Tenet Healthcare (THC) Stock Now
by Zacks Equity Research
Tenet Healthcare (THC) patient volumes are likely to remain high as seniors resume elective procedures, which were delayed due to pandemic-related constraints.
Cigna (CI) Unit to Offer ACA Plans in 350 Counties in 2024
by Zacks Equity Research
Cigna (CI) plans to expand coverage in 15 counties in North Carolina and reach an additional 200,000 ACA Marketplace clients.
Is UnitedHealth (UNH) a Good Dividend Stock Choice for You?
by Zacks Equity Research
UnitedHealth's (UNH) strong balance sheet and cash-generating ability support its endeavors to return shareholders' funds.
Down -24.4% in 4 Weeks, Here's Why You Should You Buy the Dip in atai Life Sciences N.V. (ATAI)
by Zacks Equity Research
atai Life Sciences N.V. (ATAI) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Why Prudent Investors Are Snapping Up Ensign (ENSG) Stock Now
by Zacks Equity Research
Ensign (ENSG) expects to witness strong acquisition opportunities in the fall of this year.
Here's Why Encompass Health (EHC) Stock is a Strong Buy Now
by Zacks Equity Research
Encompass Health's (EHC) focus on boosting the number of licensed beds and hospitals will likely enhance market density and build scale.
ATI Physical Therapy, Inc. (ATIP) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
ATI Physical Therapy, Inc. (ATIP) delivered earnings and revenue surprises of 0% and 1.04%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
RadNet (RDNT) Misses Q4 Earnings Estimates
by Zacks Equity Research
RadNet (RDNT) delivered earnings and revenue surprises of -42.11% and 11.24%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Addus HomeCare (ADUS) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Addus HomeCare (ADUS) delivered earnings and revenue surprises of 14.43% and 0.18%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Down -34.59% in 4 Weeks, Here's Why You Should You Buy the Dip in atai Life Sciences N.V. (ATAI)
by Zacks Equity Research
atai Life Sciences N.V. (ATAI) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
atai Life Sciences N.V. (ATAI) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
atai Life Sciences N.V. (ATAI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks Investment Ideas feature highlights: ATAI Life Sciences, Biogen and Sage
by Zacks Equity Research
ATAI Life Sciences, Biogen and Sage have been highlighted in this Investment Ideas article.
3 Biotech Stocks Aiming to Reinvent Mental Health Treatment
by Andrew Rocco
Atai, Biogen, and Sage are working to develop new treatments for mental illness.
Implied Volatility Surging for ATAI Life Sciences (ATAI) Stock Options
by Zacks Equity Research
Investors need to pay close attention to ATAI Life Sciences (ATAI) stock based on the movements in the options market lately.
The Zacks Analyst Blog Highlights: PSY, PSIL, Atai Life Sciences, COMPASS Pathways and Field Trip Health
by Zacks Equity Research
The Zacks Analyst Blog Highlights: PSY, PSIL, Atai Life Sciences, COMPASS Pathways and Field Trip Health.
3 Psychedelic Stocks to Play the Shroom Boom
by Sejuti Banerjea
Psychedelic substances are often grouped together with cannabis, but there are some important distinctions. ATAI, CMPS and FTRP are some of the best stocks in the space.